Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 111

Sort by

Sort Order Select

Journal Articles

Impact of immunochemotherapy regimens on outcomes of patients with primary mediastinal B-cell lymphoma in the IELSG37 trial

Blood (2025) 146 (23): 2758–2764.

https://doi.org/10.1182/blood.2025028823

Published: 2025

Includes: Supplemental data

Journal Articles

Indirect comparison of bendamustine-rituximab and R-CHOP with rituximab maintenance in first-line treatment of elderly Mantle Cell Lymphoma: Data from the enrich trial

Lexy Sorrell, Toby Eyre, Mats Jerkeman, Simon Rule, Dave Wright, Cathy Burton, Mark Bishton, Andrew Davies, Christopher McNamara, Kristina Sonnevi, Jon Riise, Christian Poulsen, Ingemar Lagerlöf, Ingrid Glimelius, Karin Wader, David Lewis

Blood (2025) 146 (Supplement 1): 1822.

https://doi.org/10.1182/blood-2025-1822

Published: 2025

Journal Articles

Conventional quality-of-life data analyses underestimate gains in Mantle Cell Lymphoma clinical trials: A re-examination of enrich study data

Blood (2025) 146 (Supplement 1): 1804.

https://doi.org/10.1182/blood-2025-1804

Published: 2025

Journal Articles

Prognostic impact of specific IGHV rearrangements in younger untreated Mantle Cell Lymphoma patients is independent of p53 alterations and may be modified by ibrutinib-based regimens: Insights from the TRIANGLE trial within the MULTIPLY project

Blood (2025) 146 (Supplement 1): 5299.

https://doi.org/10.1182/blood-2025-5299

Published: 2025

Journal Articles

Plasma protein ADAMTS8 as a minimally invasive favorable prognostic biomarker in mantle cell lymphoma

Ingrid Glimelius, Tove Selvin, Mattias Berglund, Rasmus Rask Kragh Jørgensen, Patrick Nylund, Karin Wader, Annika Pasanen, Won Seog Kim, Jacob Christensen, Daniel Molin, Gunilla Enblad, Mats Hellström, Mats Jerkeman

Blood (2025) 146 (Supplement 1): 3576.

https://doi.org/10.1182/blood-2025-3576

Published: 2025

Journal Articles

Ibrutinib-Rituximab Is Superior to Rituximab-Chemotherapy in Previously Untreated Older Mantle Cell Lymphoma Patients: Results from the International Randomised Controlled Trial, Enrich

Blood (2024) 144 (Supplement 1): 235.

https://doi.org/10.1182/blood-2024-199710

Published: 2024

Journal Articles

The Composition of Macrophages Has Prognostic Impact in Diffuse Large B-Cell Lymphoma By Spatial Omic Studies

Angelica Johansson, Daniel Nilsson, Lina M Olsson, Edith Gustafsson, Niamh Nihlsson, Anna Janska, Anna Porwit, Peter Hollander, Mats Jerkeman, Sara Ek

Blood (2024) 144 (Supplement 1): 2987.

https://doi.org/10.1182/blood-2024-201430

Published: 2024

Journal Articles

Survival in Mantle Cell Lymphoma Patients with a Second Primary Malignancy

Kossi D Abalo, Trine Trap, Joachim Baech, Sara Ekberg, Simon Pahnke, Alexandra Albertsson-Lindblad, Karin Ekstroem Smedby, Mats Jerkeman, Peter Brown, Thomas Stauffer Larsen, Kirsten Gronbaek, Tarec Christoffer El-Galaly, Ingrid Glimelius

Blood (2024) 144 (Supplement 1): 1638.

https://doi.org/10.1182/blood-2024-206964

Published: 2024

Journal Articles

Acalabrutinib and Rituximab in Elderly Patients with Newly Diagnosed Mantle Cell Lymphoma Including a Matched Population-Based External Comparator- the Nordic Lymphoma Group NLG-MCL8 (ALTAMIRA) Phase II Trial

Mats Jerkeman, Karin Fahl Wader, Ingrid Glimelius, Annika Pasanen, Won Seog Kim, Louise Krüger Hansen, Jon Riise, Martin Hutchings, Hashim Hussein Elhussein, Carsten Utoft Niemann, Rasmus Rask Kragh Jørgensen, Tarec Christoffer El-Galaly, Mats Ehinger, Klaus Beiske, Rose-Marie Amini, Michael Boe Møller, Marja-Liisa Karjalainen-Lindsberg, Jacob Haaber Christensen

Blood (2024) 144 (Supplement 1): 747.

https://doi.org/10.1182/blood-2024-192939

Published: 2024

Journal Articles

Timing of Disease Progression and Impact on Survival in Mantle Cell Lymphoma: A Novel Illness-Death Model Study from the Swedish Mclcomplete Project

Sara Ekberg, Ingrid Glimelius, Alexandra Albertsson-Lindblad, Karin Ekstroem Smedby, Mats Jerkeman, Caroline E Dietrich

Blood (2024) 144 (Supplement 1): 3014.

https://doi.org/10.1182/blood-2024-200664

Published: 2024

Journal Articles

Aberrant Cytoplasmic Expression of p16 Is a New Strong Prognostic Marker in Young MCL Patients Treated By Frontline Cytarabine-Based Immunochemotherapy, a Study from the Lysa Group, Nordic Lymphoma Group and the European MCL Network

Yannick Le Bris, Barbara Burroni, Marguerite Fournier, Morgane Cheminant, Sara Ek, Eva Hoster, Marie-Helene Delfau-Larue, Clémentine Sarkozy, Mary B. Callanan, Benoit Tessoulin, David Chiron, Martin Dreyling, Mats Jerkeman, Steven Le Gouill, Olivier Hermine

Blood (2024) 144 (Supplement 1): 4360.

https://doi.org/10.1182/blood-2024-199152

Published: 2024

Journal Articles

Temporal Trends in Relative Survival of Diffuse Large B-Cell Lymphoma in Sweden and Denmark in the Era of Targeted and Cellular Therapies: A Population-Based Binational Study

Sara Harrysson, Sandra Eloranta, Stefanie Antonilli, Mikkel Runason Simonsen, Kristina Sonnevi, Peter de Nully Brown, Bjorn E Wahlin, P-O Andersson, Judit Mészáros Joergensen, Mats Jerkeman, Christian Bjørn Poulsen, Gunilla Enblad, Tarec Christoffer El-Galaly, Karin Ekstroem Smedby

Blood (2024) 144 (Supplement 1): 654.

https://doi.org/10.1182/blood-2024-201964

Published: 2024

Journal Articles

Role of Autologous Stem Cell Transplantation in the Context of Ibrutinib-Containing First-Line Treatment in Younger Patients with Mantle Cell Lymphoma: Results from the Randomized Triangle Trial By the European MCL Network

Blood (2024) 144 (Supplement 1): 240.

https://doi.org/10.1182/blood-2024-200735

Published: 2024

Journal Articles

Impact of Rituximab Maintenance Added to Ibrutinib-Containing Regimens with and without ASCT in Younger, Previously Untreated MCL Patients: An Analysis of the Triangle Data Embedded in the Multiply Project

Blood (2024) 144 (Supplement 1): 237.

https://doi.org/10.1182/blood-2024-201441

Published: 2024

Journal Articles

Clonal Hematopoiesis Mutations and Cell-Free DNA Characteristics in Patients with High-Risk Large B-Cell Lymphomas

Miro Nylén, Leo Meriranta, Emil Hiitola, Maare Arffman, Harald Holte, Judit Mészáros Joergensen, Peter Brown, Sirkku Jyrkkiö, Mats Jerkeman, Øystein Fluge, Magnus Björkholm, Lars Møller Pedersen, Mikael Eriksson, Satu Mustjoki, Sirpa Leppä, Mikko Myllymäki

Blood (2024) 144 (Supplement 1): 1601.

https://doi.org/10.1182/blood-2024-201928

Published: 2024

Journal Articles

Outcomes of younger patients with mantle cell lymphoma experiencing late relapse (>24 months): the LATE-POD study

Blood (2024) 144 (9): 1001–1009.

https://doi.org/10.1182/blood.2023023525

Published: 2024

Includes: Supplemental data

Journal Articles

An International Multicohort Study of Conditional Survival and Cause of Death after Achieving Event-Free Survival at 24 Months in Patients with Mantle Cell Lymphoma

Blood (2023) 142 (Supplement 1): 1656.

https://doi.org/10.1182/blood-2023-182747

Published: 2023

Journal Articles

Survival Patterns of Non-Randomized Patients in the IELSG37 Study: Deauville Score 4 Is Not Necessarily Associated with Poor Outcome in Primary Mediastinal Lymphoma

Emanuele Zucca, Luca Ceriani, Andrew S. Davies, Giovannino Ciccone, Umberto Ricardi, Alice Di Rocco, Iryna Kryachok, Barbara Botto, Monica Balzarotti, Alessandra Tucci, Vittorio Ruggero Zilioli, Sara Usai, Luca Arcaini, Elsa Pennese, Anna Dabrowska-Iwanicka, Andrés José María Ferreri, Franceso Merli, Wei Li Zhao, David Hodgson, Codruta Ionescu, Luigi Rigacci, Claudia Cellini, Caterina Stelitano, Stefano Volpetti, Carla Minoia, Michele Spina, Alexander Fossa, George Mikhaeel, Kate Cwynarski, Andrea Janikova, Yana Stepanishyna, Mats Jerkeman, Andreas Huettmann, Maria Gomes da Silva, Don A. Stevens, Sally F Barrington, Bogdan Małkowski, Ur Metser, Annibale Versari, Stephane Chauvie, Oreste Bagni, Kelly Cozens, Sonia Perticone, Nicoletta Ielmini, Letizia Deantonio, Jan Walewski, Marek Trneny, Mary Gospodarowicz, Franco Cavalli, Peter Johnson, Maurizio Martelli

Blood (2023) 142 (Supplement 1): 1718.

https://doi.org/10.1182/blood-2023-174093

Published: 2023

Journal Articles

Exploring New Prognostic Biomarkers in Mantle Cell Lymphoma: The Best RNA Based Risk Score

Ruth Salim, Simon Husby, Christian Winther Eskelund, David W. Scott, Harald Holte, Arne Kolstad, Riikka Räty, Sara Ek, Mats Jerkeman, Christian H. Geisler, Lasse Sommer Kristensen, Mette Dahl, Kirsten Grønbæk

Blood (2022) 140 (Supplement 1): 9254–9256.

https://doi.org/10.1182/blood-2022-159472

Published: 2022

Journal Articles

A Comparison of Overall Survival with Brexucabtagene Autoleucel (Brexu-cel) CAR T-Cell Therapy (ZUMA-2) and Standard of Care (SCHOLAR-2) in Patients with Relapsed/Refractory Mantle Cell Lymphoma (R/R MCL) Previously Treated with a Covalent Bruton Tyrosine Kinase Inhibitor (BTKi)

Blood (2022) 140 (Supplement 1): 10296–10299.

https://doi.org/10.1182/blood-2022-162638

Published: 2022

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Impact of immunochemotherapy regimens on outcomes of patients with primary mediastinal B-cell lymphoma in the IELSG37 trial

Indirect comparison of bendamustine-rituximab and R-CHOP with rituximab maintenance in first-line treatment of elderly Mantle Cell Lymphoma: Data from the enrich trial

Conventional quality-of-life data analyses underestimate gains in Mantle Cell Lymphoma clinical trials: A re-examination of enrich study data

Prognostic impact of specific IGHV rearrangements in younger untreated Mantle Cell Lymphoma patients is independent of p53 alterations and may be modified by ibrutinib-based regimens: Insights from the TRIANGLE trial within the MULTIPLY project

Plasma protein ADAMTS8 as a minimally invasive favorable prognostic biomarker in mantle cell lymphoma

Ibrutinib-Rituximab Is Superior to Rituximab-Chemotherapy in Previously Untreated Older Mantle Cell Lymphoma Patients: Results from the International Randomised Controlled Trial, Enrich

The Composition of Macrophages Has Prognostic Impact in Diffuse Large B-Cell Lymphoma By Spatial Omic Studies

Survival in Mantle Cell Lymphoma Patients with a Second Primary Malignancy

Acalabrutinib and Rituximab in Elderly Patients with Newly Diagnosed Mantle Cell Lymphoma Including a Matched Population-Based External Comparator- the Nordic Lymphoma Group NLG-MCL8 (ALTAMIRA) Phase II Trial

Timing of Disease Progression and Impact on Survival in Mantle Cell Lymphoma: A Novel Illness-Death Model Study from the Swedish Mclcomplete Project

Aberrant Cytoplasmic Expression of p16 Is a New Strong Prognostic Marker in Young MCL Patients Treated By Frontline Cytarabine-Based Immunochemotherapy, a Study from the Lysa Group, Nordic Lymphoma Group and the European MCL Network

Temporal Trends in Relative Survival of Diffuse Large B-Cell Lymphoma in Sweden and Denmark in the Era of Targeted and Cellular Therapies: A Population-Based Binational Study

Role of Autologous Stem Cell Transplantation in the Context of Ibrutinib-Containing First-Line Treatment in Younger Patients with Mantle Cell Lymphoma: Results from the Randomized Triangle Trial By the European MCL Network

Impact of Rituximab Maintenance Added to Ibrutinib-Containing Regimens with and without ASCT in Younger, Previously Untreated MCL Patients: An Analysis of the Triangle Data Embedded in the Multiply Project

Clonal Hematopoiesis Mutations and Cell-Free DNA Characteristics in Patients with High-Risk Large B-Cell Lymphomas

Outcomes of younger patients with mantle cell lymphoma experiencing late relapse (>24 months): the LATE-POD study

An International Multicohort Study of Conditional Survival and Cause of Death after Achieving Event-Free Survival at 24 Months in Patients with Mantle Cell Lymphoma

Survival Patterns of Non-Randomized Patients in the IELSG37 Study: Deauville Score 4 Is Not Necessarily Associated with Poor Outcome in Primary Mediastinal Lymphoma

Exploring New Prognostic Biomarkers in Mantle Cell Lymphoma: The Best RNA Based Risk Score

A Comparison of Overall Survival with Brexucabtagene Autoleucel (Brexu-cel) CAR T-Cell Therapy (ZUMA-2) and Standard of Care (SCHOLAR-2) in Patients with Relapsed/Refractory Mantle Cell Lymphoma (R/R MCL) Previously Treated with a Covalent Bruton Tyrosine Kinase Inhibitor (BTKi)

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only